Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Isotretinoin revisited.

A R Shalita1, R B Armstrong, J J Leyden

  • 1Department of Dermatology, State University of New York Health Science Center, Brooklyn.

Cutis
|December 29, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of an atrophic acne scar risk assessment tool.

Journal of the European Academy of Dermatology and Venereology : JEADV·2017
Same author

4-Hexyl-1,3-phenylenediol, a nuclear factor-κB inhibitor, improves photodamaged skin and clinical signs of ageing in a double-blinded, randomized controlled trial.

The British journal of dermatology·2015
Same author

Skin surface microflora of the saddle-back tamarin monkey,Saguinus fuscicollis.

Journal of chemical ecology·2013
Same author

Analysis of characteristic odors from human male axillae.

Journal of chemical ecology·2013
Same author

An investigation of human apocrine gland secretion for axillary odor precursors.

Journal of chemical ecology·2013
Same author

Analysis of characteristic human female axillary odors: Qualitative comparison to males.

Journal of chemical ecology·2013
Same journal

A Solitary Axillary Subcutaneous Mass.

Cutis·2026
Same journal

Microcystic Adnexal Carcinoma-like Neoplasm in a Patient With POT1 Mutation.

Cutis·2026
Same journal

A Hybrid Suture Technique: Suture Modification With Dental Roll Insertion.

Cutis·2026
Same journal

Beyond Conventional Paradigms: Rethinking the Evaluation and Management of Melasma.

Cutis·2026
Same journal

Social Drivers of Health Curriculum for Dermatology Residents: the UCSF Experience.

Cutis·2026
Same journal

Hospital Dermatology: Review of Research in 2024-2025.

Cutis·2026
See all related articles

Isotretinoin effectively treats severe acne, offering prolonged remission. However, due to risks of birth defects, pregnant women must avoid this medication, with a one-month gap advised before conception.

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Severe, recalcitrant nodulocystic acne often requires potent treatment beyond oral antibiotics.
  • Isotretinoin (13-cis-retinoic acid) is a primary therapeutic agent for such severe acne cases.
  • The drug demonstrates significant efficacy in clearing lesions and achieving long-term remission.

Purpose of the Study:

  • To review the efficacy and safety profile of isotretinoin for severe acne treatment.
  • To highlight the critical need for preventing isotretinoin exposure during pregnancy.
  • To provide recommendations for managing and minimizing potential side effects.

Main Methods:

  • Review of existing literature on isotretinoin's use in dermatology.
  • Analysis of data regarding treatment outcomes, remission durations, and adverse events.

Related Experiment Videos

  • Examination of pharmacokinetic properties relevant to pregnancy risk and discontinuation.

    • Main Results:

    • Isotretinoin provides dramatic lesion clearing and prolonged remissions, potentially dose and duration-dependent.
    • Significant teratogenic risks necessitate strict pregnancy prevention measures.
    • Common side effects include mucocutaneous reactions, lipid changes, eye irritation, and myalgias; rarer effects include hyperostoses and pseudotumor cerebri.

    Conclusions:

    • Isotretinoin is a highly effective treatment for severe acne, but its teratogenicity demands rigorous safety protocols.
    • A one-month post-treatment interval allows for safe conception due to rapid drug elimination.
    • Management strategies can mitigate common and rare adverse effects associated with isotretinoin therapy.